NCT07018869|RecruitingPhase 3DMC

Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

A Pragmatic Randomized Controlled Trial to Evaluate the Effectiveness of an Intervention Called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance

SWOG Cancer Research Network ClinicalTrials.gov

Compare

5 other identifiers

S2417CDNCI-2025-03080SWOG-S2417CDR01CA293394UG1CA189974

Study Type

interventional

Target

1,057

Locations

3 countries

Sites

384

Timeline

RegisteredJun 2025

StartedOct 2025

CompletionJun 2029

Brief Summary

This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that aligns with current guidelines (guideline-concordant). Surveillance care after resection of colorectal cancer is critical to detect potentially curable return of disease (recurrence), yet up to 60% of colorectal cancer survivors fail to receive surveillance. This may be due to a lack of knowledge about the purpose of surveillance care and the risks of cancer recurrence, or a lack of confidence for managing surveillance care. The CTAC intervention is an online education intervention designed to improve patients' knowledge about surveillance and their self-efficacy for managing surveillance, and to promote effective communication with supporters and supporter engagement in patients' surveillance in a way that is aligned with each patient's preferences. By increasing a patient's knowledge, self-efficacy, and satisfaction with their supporter's engagement in their care, the CTAC intervention may increase the number of patients who receive guideline-concordant surveillance care after resection of colorectal cancer.

Trial Health

On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment

1,057

participants targeted

Target at P75+ for phase_3

Timeline

36mo left

Started Oct 2025

Typical duration for phase_3

Geographic Reach

3 countries

384 active sites

Status

recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

3.6 years study duration

Study Progress18%

Oct 2025Jun 2029

First Submitted

Initial submission to the registry

May 21, 2025

Completed

23 days until next milestone

First Posted

Study publicly available on registry

June 13, 2025

Completed

4 months until next milestone

Study Start

First participant enrolled

October 15, 2025

Completed

3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 23, 2029

Expected

14 days until next milestone

Study Completion

Last participant's last visit for all outcomes

June 6, 2029

Last Updated

March 31, 2026

Status Verified

December 1, 2025

Enrollment Period

3.6 years

First QC Date

May 21, 2025

Last Update Submit

March 25, 2026

Conditions

Colorectal Cancer Stage II Colorectal Cancer Stage III

Outcome Measures

Primary Outcomes (1)

Receipt of colorectal cancer surveillance
Receipt of the four surveillance components will be abstracted as a binary outcome (yes versus no) from the electronic medical record for every enrolled patient. Additionally, patient-reported receipt of surveillance will be collected via survey. Multivariable logistic regression will be used, adjusted for the stratification factors as covariates.
At 16 months

Secondary Outcomes (6)

Knowledge About Colorectal Follow-Up Care score
At baseline, 3 months, and 16 months
Cancer Worry Scale (CWS)
At baseline, 3 months, and 16 months
Follow-up care preferences questionnaire
At baseline, 3 months, and 16 months
Self-efficacy for managing follow-up care
At baseline, 3 months, and 16 months
Patient Reported Outcomes Measurement Information System (PROMIS)-29 + 2 Profile version 2.1, Physical Function Measure only
At baseline, 3 months, and 16 months
+1 more secondary outcomes

Other Outcomes (2)

Barriers and facilitators of intervention uptake and use
Up to 16 months
Supporter participation/inclusion in the assigned intervention
Up to 16 months

Study Arms (2)

Group 1 (CTAC)

EXPERIMENTAL

Patients and supporter participants receive access to the CTAC intervention website and may review the content as frequently as they like for up to 16 months on study.

Other: Intervention website accessOther: InterviewOther: Questionnaire Administration

Group 2 (Control)

ACTIVE COMPARATOR

Patients and supporter participants receive access to a general health education website and may review the content as frequently as they like for up to 16 months on study.

Other: Control website accessOther: InterviewOther: Questionnaire Administration

Interventions

Intervention website accessOTHER

Receive access to CTAC intervention website with educational content and interactive modules

Group 1 (CTAC)

Control website accessOTHER

Receive access to CTAC control website with general health education

Group 2 (Control)

InterviewOTHER

Ancillary studies

Group 1 (CTAC)Group 2 (Control)

Questionnaire AdministrationOTHER

Ancillary studies

Group 1 (CTAC)Group 2 (Control)

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

PATIENTS:
Patient participants must have newly diagnosed surgically resected, stage II or stage III colorectal cancer per the timing described below
Patient participants must have an adult in their life who supports them in their colorectal cancer journey who they might be willing to invite to join them in viewing an educational website. This is determined via the question: "Do you have an adult in your life, such as a spouse/partner, family member or friend, who supports you with your colorectal cancer journey and may be willing to view a website with you? When we say, "supports you in your colorectal cancer journey", we mean things like, helping you keep and get to medical appointments, talking with you and/or your doctors about your cancer, or helping you make decisions about your cancer."
Those who respond "no" to the question above will be told that "Because this study is for patients and a supporter to view the website together, you are not eligible for this study, but there may be other studies you are eligible for in the future".
NOTE: The above question will be used to define "supporter" for purposes of this study. Examples of supporters include a spouse, partner, sibling, adult child, another family member, or friend.
NOTE: The supporter does not have to agree to participate in the study in order for the patient to be eligible for this study. Justification for requiring the enrolled patient to have a supporter (whether the supporter is invited or participates) is based on the study's underlying conceptual framework
Patient participants must not have recurrent or metastatic (stage IV) colorectal cancer
Patient participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the efficacy assessment of this intervention
Patient participants must be registered within 90 - 180 days of surgical resection
Patient participants must be ≥ 18 years of age at the time of registration/randomization. The lower cutoff of 18 was determined because the lower age range of patients that may be recruited to Southwest Oncology Group (SWOG) studies is 18
Patient participants must have Zubrod performance status of 0-2
Patient participants must be able to read English or Spanish since the website for the intervention and control arm are available in English and Spanish
Patient participants must: 1) be able to complete Patient Reported Outcome (PRO) questionnaires in English or Spanish, and 2) agree to complete PROs at all scheduled timepoints
Patient participants will be encouraged to provide an email address or cell phone number, if possible, for the purpose of being contacted by staff at the University of Michigan who will provide access to the educational website. For those who do not wish to provide or create an email address or a cell phone number, they may still participate with alternate methods
Patient participants must not be enrolled or be planning to enroll in a clinical trial of investigational treatment that includes imaging and/or laboratory monitoring for the duration of this trial
+8 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

SWOG Cancer Research Networklead
National Cancer Institute (NCI)collaborator

Study Sites (384)

Anchorage Associates in Radiation Medicine

Anchorage, Alaska, 98508, United States

RECRUITING

Alaska Breast Care and Surgery LLC